Results of ProfiLER-2, a multicentre, prospective study comparing a hospital homemade control gene panel (CTL) to "the commercially available Foundation OneCDX (F1CDX).." was recently published in Nature Medicine. Of the 741 patients with solid tumours screened in this study, molecular-based recommended therapies were identified with F1CDX in 175 patients and CTL in 125 patients, representing a 14.8% increase when using the F1CDX gene panel.
To read more about this study, click here.
Source mentioned:
Trédan O, Pouessel D, Penel N, et al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. Nature Medicine; Published online 7 April 2025. DOI: https://doi.org/10.1038/s41591-025-03613-x
No comments:
Post a Comment